Del Mar Medical Devices acquires NovaldMedical.com
NovaldMedical.com is a life sciences and materials science company that specializes in using Atomic Layer Deposition (ALD) — a technology for applying extremely thin, controlled coatings — to improve drug delivery systems, pharmaceutical manufacturing, and medical devices.
Here’s a clearer breakdown of what they do:
What NovaldMedical Does:
Thin Film Coatings for Pharmaceuticals and Medical Devices
→ They apply nanoscale coatings to drugs, devices, and lab equipment to improve things like:Drug stability
Controlled drug release
Biocompatibility
Surface sensitivity (for diagnostics)
Surface Engineering via Atomic Layer Deposition (ALD)
→ ALD allows them to create precise, custom surfaces that can withstand harsh conditions or modify how materials interact biologically, without damaging heat-sensitive drugs.Consulting and Strategic Product Development
→ They work with pharmaceutical and biotech companies to develop new drug delivery technologies, coatings for medical devices, and improve pharmaceutical manufacturing processes.Experimental Coatings and R&D Services
→ Companies can send NovaldMedical.com specimens (e.g., drugs, devices) to test new coating solutions or manufacturing optimizations.
Del Mar Medical Devices has acquired NovaldMedical.com to enhance its long-term investment strategy and better serve its healthcare-focused client base. By integrating a leading innovator in drug delivery and medical device surface technologies, Del Mar strengthens its defined benefit plan offerings with a durable, high-growth asset. NovaldMedical.com’s expertise aligns with the consistent growth of the healthcare sector, helping match stable earnings with long-term pension obligations. In addition to diversification, the acquisition gives Del Mar greater control over cash-producing assets like licensing revenues and royalties, while offering the potential for high-value exits in the future.
NovaldMedical.com’s strong intellectual property portfolio, combined with its advances in pharmaceutical surface engineering, adds a non-correlated, defensive layer to Del Mar’s investment portfolio. This move not only enhances portfolio resilience but also opens new opportunities to deliver specialized investment solutions for the physicians, dentists, and healthcare professionals Del Mar serves. The acquisition reflects Del Mar’s broader commitment to innovation, stability, and long-term value creation across the healthcare and life sciences markets.
If your life sciences business has a multi-member pension plan, we can manage it or make an offer on the business to buy it—whether your company is growing, continuing operations, or winding down.
